AB001 advances into Phase 2
ARTBIO’s Series B announcement funds AB001 through Phase II development. Moving into that phase is distinct from its existing ARTISAN Phase 1 dosing.
What matters
Track what the company has actually announced, the study or asset involved, and the evidence needed to confirm the milestone.
- Research candidate, not a live market, clinical probability, company equity or access to private shares.
Primary evidence
Company development objective — Phase 2 date unconfirmed
Company context
Company-authored LinkedIn About explicitly states Type: Privately Held and links artbio.com. Opened and checked October 31, 2026. This is an undated company self-report, not independent registry proof. Its investor Sofinnova also lists Status Private, but company self-report is the classification source here.
Potential outcome market
Will a participant receive AB001 in a qualifying Phase 2 prostate-cancer trial by the market deadline?
This event is research, not a listed market. A market needs a precise question, resolution rules and liquidity before trading opens.